Company profile
Satellos Bioscience Inc.
NASDAQ: MSLE · Healthcare · Biotechnology
Canadian filerHQ Toronto, ONReports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH 50DQ —GM —SS 49
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$24.9M
Employees
18
as of 2026-08-22
Market cap
$12.9M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$24.9M-$24.9M2025
Operating income-$26.5M-$26.5M2025
Total assets$31.9M$31.9M2025
Liabilities$4.1M$4.1M2025
Equity$27.8M$27.8M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Satellos Bioscience Inc.’s revenue?
Satellos Bioscience Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Adagio Medical Holdings, Inc.24DSynlogic, Inc.45DPhio Pharmaceuticals Corp.41DCaptiva Verde Wellness Corp.——Kiora Pharmaceuticals, Inc.51DIzotropic Corporation——Key facts
CEOFrank Gleeson
SectorHealthcare
IndustryBiotechnology
HeadquartersToronto, ON
ExchangeNASDAQ: MSLE
Employees18
IPO date2012-08-03
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.